Jentadueto Tablet, Film Coated
Product Images NDC 0597-0146

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Jentadueto (NDC 0597-0146). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Boehringer Ingelheim Pharmaceuticals, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Jentadueto 01

Chemical structure of linagliptin and metformin hydrochloride, the active ingredients in Jentadueto oral film-coated tablets by Boehringer Ingelheim Pharmaceuticals, Inc.*

FDA Label Image

Jentadueto 02

Chemical structure of linagliptin, one of the active ingredients in Jentadueto tablets, combined with hydrochloride (HCl). The diagram shows the molecular structure with nitrogen, hydrogen, carbon, and methyl groups indicated.*

FDA Label Image

Jentadueto 03

A line graph depicting the adjusted mean percent change from baseline in A1C levels over 24 weeks across six groups: placebo, linagliptin 5 mg once daily, metformin 500 mg twice daily, metformin 1000 mg twice daily, linagliptin 2.5 mg plus metformin 500 mg twice daily, and linagliptin 2.5 mg plus metformin 1000 mg twice daily. The x-axis shows time in weeks, and the y-axis represents percent change in A1C. The graph includes a legend identifying each treatment group by symbol.*

FDA Label Image

Jentadueto 04

A Kaplan-Meier curve showing the percentage of patients with an event over approximately 3.5 years comparing placebo and linagliptin groups. The y-axis represents patients with event (%) and the x-axis represents time in years. The graph includes numbers of patients at risk at different time points for both groups.*

FDA Label Image

Jentadueto 05

A line graph comparing the percentage of patients with an event over a 7-year period for Linagliptin and Glimepiride treatments. The x-axis represents years from 0 to 7, and the y-axis shows the percentage of patients with the event from 0% to 16%. Two lines track event rates for each drug, with patient numbers at risk listed below the x-axis for each year.*

FDA Label Image

Jentadueto 06

FDA Label Image

Jentadueto 07

Label for Jentadueto tablets containing linagliptin and metformin hydrochloride, 2.5 mg/850 mg strength. The label indicates 60 film-coated tablets, oral route, and is distributed by Boehringer Ingelheim Pharmaceuticals, Inc. It includes storage instructions and dosage information references.*

FDA Label Image

Jentadueto 08

Jentadueto 2.5 mg/1000 mg film-coated tablets label for oral use. Contains linagliptin and metformin hydrochloride. The label indicates a package size of 60 tablets, distributed by Boehringer Ingelheim Pharmaceuticals, Inc. Storage instructions specify 20°C to 25°C with permitted excursions. The label also includes NDC 0597-0148-60 and barcode information.*

FDA Label Image

Jentadueto 09

Label for Jentadueto 2.5 mg/500 mg film-coated tablets containing linagliptin and metformin hydrochloride. The label shows the product name, strength, dosage form, 60 tablet count, and manufacturer Boehringer Ingelheim Pharmaceuticals, Inc. It includes storage instructions and a dispensing note to provide a medication guide with each patient.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.